Radnor Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.18M | Buy |
28,539
+4,670
| +20% | +$1M | 1.01% | 20 |
|
|
2026
Q1 | $5.19M | Sell |
23,869
-175
| -0.7% | -$38.8K | 0.77% | 25 |
|
|
2025
Q4 | $5.49M | Sell |
24,044
-1,023
| -4% | -$233K | 0.82% | 23 |
|
|
2025
Q3 | $5.8M | Sell |
25,067
-123
| -0.5% | -$25K | 0.88% | 20 |
|
|
2025
Q2 | $4.68M | Buy |
25,190
+629
| +3% | +$117K | 0.75% | 26 |
|
|
2025
Q1 | $5.15M | Sell |
24,561
-86
| -0.3% | -$16.7K | 0.86% | 20 |
|
|
2024
Q4 | $4.38M | Sell |
24,647
-3,268
| -12% | -$601K | 0.73% | 27 |
|
|
2024
Q3 | $5.51M | Buy |
27,915
+2,561
| +10% | +$478K | 0.82% | 20 |
|
|
2024
Q2 | $4.35M | Buy |
25,354
+260
| +1% | +$43.1K | 1.33% | 12 |
|
|
2024
Q1 | $4.57M | Sell |
25,094
-2,591
| -9% | -$447K | 0.78% | 20 |
|
|
2023
Q4 | $4.29M | Buy |
27,685
+273
| +1% | +$39.8K | 0.8% | 20 |
|
|
2023
Q3 | $4.09M | Buy |
27,412
+2,017
| +8% | +$296K | 0.81% | 21 |
|
|
2023
Q2 | $3.42M | Buy |
25,395
+8,829
| +53% | +$1.29M | 1.46% | 10 |
|
|
2023
Q1 | $2.64M | Buy |
16,566
+1,200
| +8% | +$183K | 0.69% | 31 |
|
|
2022
Q4 | $2.53M | Sell |
15,366
-707
| -4% | -$108K | 0.62% | 35 |
|
|
2022
Q3 | $2.16M | Sell |
16,073
-40
| -0.2% | -$5.74K | 0.63% | 33 |
|
|
2022
Q2 | $2.47M | Buy |
16,113
+469
| +3% | +$71.7K | 0.68% | 33 |
|
|
2022
Q1 | $2.54M | Buy |
15,644
+433
| +3% | +$62.9K | 0.64% | 39 |
|
|
2021
Q4 | $2.06M | Buy |
15,211
+3,307
| +28% | +$391K | 0.51% | 53 |
|
|
2021
Q3 | $1.28M | Buy |
11,904
+450
| +4% | +$51.4K | 0.76% | 24 |
|
|
2021
Q2 | $1.29M | Buy |
11,454
+150
| +1% | +$16.9K | 0.44% | 60 |
|
|
2021
Q1 | $1.22M | Buy |
11,304
+300
| +3% | +$32.1K | 0.39% | 64 |
|
|
2020
Q4 | $1.18M | Buy |
11,004
+535
| +5% | +$51.4K | 0.33% | 66 |
|
|
2020
Q3 | $917K | Buy |
10,469
+850
| +9% | +$80K | 0.31% | 75 |
|
|
2020
Q2 | $954K | Buy |
9,619
+1,444
| +18% | +$127K | 0.34% | 67 |
|
|
2020
Q1 | $622K | Hold |
8,175
| – | – | 0.26% | 83 |
|
|
2019
Q4 | $724K | Hold |
8,175
| – | – | 0.22% | 96 |
|
|
2019
Q3 | $619K | Hold |
8,175
| – | – | 0.2% | 104 |
|
|
2019
Q2 | $594K | Buy |
8,175
+3,850
| +89% | +$303K | 0.2% | 104 |
|
|
2019
Q1 | $349K | Sell |
4,325
-775
| -15% | -$63.4K | 0.11% | 138 |
|
|
2018
Q4 | $470K | Hold |
5,100
| – | – | 0.17% | 112 |
|
|
2018
Q3 | $482K | Buy |
5,100
+500
| +11% | +$47.4K | 0.15% | 122 |
|
|
2018
Q2 | $426K | Hold |
4,600
| – | – | 0.16% | 124 |
|
|
2018
Q1 | $435K | Sell |
4,600
-391
| -8% | -$43K | 0.15% | 140 |
|
|
2017
Q4 | $483K | Sell |
4,991
-100
| -2% | -$9.43K | 0.15% | 135 |
|
|
2017
Q3 | $369K | Hold |
5,091
| – | – | 0.12% | 141 |
|
|
2017
Q2 | $369K | Sell |
5,091
-870
| -15% | -$58.5K | 0.12% | 141 |
|
|
2017
Q1 | $388K | Hold |
5,961
| – | – | 0.13% | 136 |
|
|
2016
Q4 | $373K | Buy |
+5,961
| New | +$364K | 0.13% | 142 |
|
Other funds holding ABBV
Radnor Capital Management's ABBV Position: Q2 2026 in Review
Radnor Capital Management increased its AbbVie (ABBV) stake by 20% in Q2 2026, buying an estimated $1M and bringing the position to 28,539 shares worth $7.18M. The position accounts for 1.01% of the portfolio, ranked #20.
Radnor Capital Management first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Radnor Capital Management held 28,539 shares of AbbVie worth $7.18M as of Q2 2026.
- Radnor Capital Management bought 4,670 AbbVie shares in Q2 2026, an estimated $1M.
- AbbVie made up 1.01% of Radnor Capital Management's portfolio in Q2 2026, its #20 holding.
- Radnor Capital Management first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Radnor Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.